Physician
Schulz, Rex
Schulz, Rex was paid $2.40M by Medicaid between Jan 2018 and Aug 2024, across 128 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 15% of everything it billed.
33Billing provider infoSCHULZ, REX
QUINCY, IL 62301
QUINCY, IL 62301
33aNPI1780707703assigned 04/06/2007
33bProvider typeClinical Pathology/Laboratory Medicine Physician
28Total paid$2.40M
24GClaims537,493
24DCodes billed128
24AFirst – last monthJan 2018 – Aug 2024
Compared with peers
Next to other Clinical Pathology/Laboratory Medicine Physician providers in Illinois
Rank by total paid#5 of 34
Median peer was paid$104K
This provider vs. median23×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 258 | $6K | |
| 2019 | 13,522 | $59K | |
| 2020 | 108,634 | $462K | |
| 2021 | 124,638 | $588K | |
| 2022 | 118,053 | $542K | |
| 2023 | 113,300 | $489K | |
| 2024incomplete | 59,088 | $256K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 15% | 70,147 | 37,236 | $362K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 8.2% | 68,378 | 36,052 | $197K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 4.6% | 9,144 | 6,872 | $111K |
| 83735 | 4.6% | 32,030 | 15,145 | $110K | |
| 84443 | Thyroid stimulating hormone (TSH) | 4.3% | 12,759 | 11,112 | $104K |
| 87040 | 3.3% | 7,616 | 4,697 | $80K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 2.5% | 7,008 | 5,121 | $61K |
| 83605 | 2.5% | 11,533 | 6,425 | $59K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.3% | 12,787 | 6,888 | $54K |
| 84484 | 2.2% | 10,752 | 6,661 | $53K | |
| 87088 | 2.2% | 7,491 | 6,261 | $52K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.8% | 8,322 | 6,877 | $43K |
116 more codes
| 82805 | 1.8% | 5,485 | $43K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.7% | 3,510 | $42K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.7% | 3,499 | $42K |
| 86141 | 1.6% | 4,680 | $39K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.6% | 3,794 | $38K |
| 85027 | 1.6% | 13,052 | $37K | |
| 83690 | 1.5% | 10,792 | $36K | |
| 80061 | Lipid panel | 1.3% | 8,620 | $32K |
| 83880 | 1.3% | 2,777 | $31K | |
| 85730 | 1.3% | 9,481 | $31K | |
| 82962 | 1.3% | 16,089 | $31K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.2% | 4,871 | $28K |
| 87070 | 1.2% | 9,067 | $28K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 2,300 | $28K |
| 87186 | 1.1% | 4,426 | $27K | |
| 84100 | 1.1% | 12,076 | $27K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.1% | 859 | $26K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,022 | $24K |
| 82607 | <1% | 3,917 | $23K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,055 | $23K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,351 | $23K |
| 85610 | <1% | 11,781 | $23K | |
| 87641 | <1% | 1,774 | $22K | |
| 84703 | <1% | 6,041 | $21K | |
| 81001 | <1% | 14,095 | $20K | |
| 86850 | <1% | 5,350 | $16K | |
| 85379 | <1% | 3,937 | $15K | |
| 82746 | <1% | 2,583 | $15K | |
| 81025 | <1% | 6,006 | $15K | |
| 86901 | <1% | 6,484 | $15K | |
| 84439 | <1% | 3,084 | $14K | |
| 83970 | <1% | 1,018 | $12K | |
| 80202 | <1% | 1,622 | $12K | |
| 83550 | <1% | 2,859 | $12K | |
| 82728 | <1% | 2,775 | $11K | |
| 86900 | <1% | 6,476 | $11K | |
| 84702 | <1% | 2,411 | $11K | |
| 87480 | <1% | 891 | $11K | |
| 82330 | <1% | 1,314 | $10K | |
| 87340 | <1% | 1,576 | $10K | |
| 87510 | <1% | 861 | $10K | |
| 87205 | <1% | 5,289 | $10K | |
| 83540 | <1% | 3,009 | $10K | |
| 87660 | <1% | 1,081 | $9K | |
| 82570 | <1% | 3,109 | $8K | |
| 81003 | <1% | 7,092 | $8K | |
| 86038 | <1% | 1,170 | $7K | |
| 86803 | <1% | 803 | $7K | |
| 84481 | <1% | 1,264 | $6K | |
| 82550 | <1% | 2,020 | $6K | |
| 83615 | <1% | 1,836 | $5K | |
| 86592 | <1% | 2,449 | $5K | |
| 80074 | <1% | 387 | $5K | |
| 87400 | <1% | 743 | $4K | |
| 86920 | <1% | 919 | $4K | |
| 84550 | <1% | 1,928 | $4K | |
| 85652 | <1% | 2,939 | $4K | |
| 80076 | <1% | 987 | $4K | |
| 82947 | <1% | 1,962 | $4K | |
| 85018 | <1% | 2,932 | $4K | |
| 85014 | <1% | 2,903 | $3K | |
| 86762 | <1% | 791 | $3K | |
| 82043 | <1% | 1,713 | $3K | |
| 86880 | <1% | 997 | $3K | |
| 87015 | <1% | 828 | $3K | |
| 84134 | <1% | 676 | $3K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 206 | $2K |
| 80050 | General health panel | <1% | 290 | $2K |
| 87420 | <1% | 267 | $2K | |
| 82009 | <1% | 1,613 | $2K | |
| 87081 | <1% | 662 | $2K | |
| 87210 | <1% | 784 | $2K | |
| 84156 | <1% | 1,558 | $2K | |
| 84145 | <1% | 2,693 | $2K | |
| 87220 | <1% | 686 | $2K | |
| 82950 | <1% | 640 | $1K | |
| 87147 | <1% | 887 | $1K | |
| 85385 | <1% | 301 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 55 | $1K |
| 82150 | <1% | 405 | $1K | |
| 84153 | <1% | 181 | $1K | |
| 81002 | <1% | 776 | $977.14 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 80 | $969.60 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 77 | $933.24 |
| 87493 | <1% | 82 | $817.83 | |
| 86431 | <1% | 202 | $730.46 | |
| 87899 | <1% | 63 | $691.63 | |
| 87581 | <1% | 55 | $666.60 | |
| 87486 | <1% | 55 | $666.60 | |
| 89051 | <1% | 170 | $623.20 | |
| 82247 | <1% | 230 | $529.32 | |
| 85046 | <1% | 196 | $512.78 | |
| 88300 | <1% | 88 | $510.95 | |
| 87045 | <1% | 73 | $448.95 | |
| 82248 | <1% | 214 | $436.79 | |
| 80164 | <1% | 79 | $347.44 | |
| 87075 | <1% | 52 | $345.88 | |
| 86738 | <1% | 67 | $328.84 | |
| 82977 | <1% | 128 | $319.44 | |
| 80051 | <1% | 88 | $292.26 | |
| 86039 | <1% | 52 | $274.91 | |
| 82140 | <1% | 51 | $234.29 | |
| 88304 | <1% | 14 | $222.15 | |
| 84112 | <1% | 27 | $160.55 | |
| 87046 | <1% | 73 | $160.52 | |
| 86705 | <1% | 14 | $108.10 | |
| 84300 | <1% | 46 | $95.40 | |
| 86706 | <1% | 13 | $91.14 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 15 | $84.70 |
| 86769 | <1% | 12 | $72.60 | |
| 86255 | <1% | 16 | $54.27 | |
| 86308 | <1% | 16 | $38.45 | |
| 89050 | <1% | 16 | $28.08 | |
| 89055 | <1% | 12 | $17.88 | |
| 0100U | 0% | 66 | $0.00 | |
| 87077 | 0% | 592 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.